US FDA review finds no evidence linking GLP-1 receptor agonists in popular medicines like Wegovy and Zepbound to an increased risk of suicidal thoughts or behaviour ...

Obesity took center stage on the first day of the 2026 J.P. Morgan Healthcare Conference, with industry frontrunners Eli ...

Amgen is hoping to gain a slice of the obesity market with MariTide, which it claims has a differentiated profile to other approved incretin therapies.

The warnings, part of their original approval, were based ​on reports of such events observed with a variety of older ...

Nvidia eyes first breakout of 2026. These clues — and an innovative deal with Eli Lilly — bode well.